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Background: Insulin resistance (IR) assessed by the Homeostatic Model Assessment (HOMA) index in the acute
phase of myocardial infarction in non-diabetic patients was recently established as an independent predictor of
intrahospital mortality. In this study we postulated that acute IR is a dynamic phenomenon associated with the
development of myocardial and microvascular injury and larger final infarct size in patients with ST-segment
elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI).
Methods: In 104 consecutive patients with the first anterior STEMI without diabetes, the HOMA index was
determined on the 2nd and 7th day after pPCI. Worst-lead residual ST-segment elevation (ST-E) on postprocedural
ECG, coronary flow reserve (CFR) determined by transthoracic Doppler echocardiography on the 2nd day after pPCI
and fixed perfusion defect on single-photon emission computed tomography myocardial perfusion imaging
(SPECT-MPI) determined six weeks after pPCI were analyzed according to HOMA indices.
Results: IR was present in 55 % and 58 % of patients on day 2 and day 7, respectively. Incomplete post-procedural
ST-E resolution was more frequent in patients with IR compared to patients without IR, both on day 2 (p = 0.001)
and day 7 (p < 0.001). The HOMA index on day 7 correlated with SPECT-MPI perfusion defect (r = 0.331), whereas
both HOMA indices correlated well with CFR (r = −0.331 to −0.386) (p < 0.01 for all). In multivariable backward logistic
regression analysis adjusted for significant univariate predictors and potential confounding variables, IR on day 2 was
an independent predictor of residual ST-E ≥ 2 mm (OR 11.70, 95% CI 2.46-55.51, p = 0.002) and CFR < 2 (OR = 5.98, 95%
CI 1.88-19.03, p = 0.002), whereas IR on day 7 was an independent predictor of SPECT-MPI perfusion defect > 20%
(OR 11.37, 95% CI 1.34-96.21, p = 0.026).
Conclusion: IR assessed by the HOMA index during the acute phase of the first anterior STEMI in patients without
diabetes treated by pPCI is independently associated with poorer myocardial reperfusion, impaired coronary
microcirculatory function and potentially with larger final infarct size.
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Full myocardial reperfusion with restoration of coronary
microcirculatory function (CMF) is a therapeutic goal in
ST-segment elevation myocardial infarction (STEMI) [1].
Despite successful primary percutaneous intervention
(pPCI) it is not achieved in 30% to 50% of patients [2,3].
The reasons are complex, and include also several meta-
bolic issues [3].
Insulin resistance (IR) as a part of metabolic syndrome
is an important risk factor for the development of cardiac
and vascular impairments [4,5] and carries ominous
prognosis in the setting of acute myocardial infarction
[6]. As a part of metabolic syndrome IR is associated
with myocardial and microvascular injury after STEMI in
clinical [7,8] and experimental studies [9]. Data connect-
ing metabolic syndrome to the final infarct size are less
clear [10-12]. However, emerging evidences support direct
proatherogenic effects of IR [13-15], as well as its dir-
ect adverse effects on myocardial contractility [16]. As
phenomenon per se, independent of other components of
metabolic syndrome, IR was related to ischemic myocar-
dial injury after elective PCI [17].
Recently, IR in the early phase of acute coronary syn-
drome in non-diabetic patients, assessed by the homeo-
static model assessment (HOMA) index, was established
as an independent predictor of in-hospital mortality
[18-21]. This “acute” IR is a part of the acute glycometa-
bolic response to stress, can be transient and can occur
even in patients without chronic glycometabolic derange-
ments [22]. Data regarding the relationships between acute
IR and CMF after pPCI are scarce. Acute IR comprises
acute hyperglycemia and/or acute hyperinsulinemia [23].
Hyperglycemia in STEMI patients has direct acute negative
cardiovascular effects contributing to incomplete myocar-
dial reperfusion and CMF impairment [24-28]. The prog-
nostic relevance of hyperinsulinemia in STEMI patients
[29,30] and its relationship with coronary flow [31] are less
well evaluated and acknowledged.
We postulate that IR can occur in the early post pPCI
period as a dynamic phenomenon even in non-diabetic
patients, and be related to the development of micro-
vascular and myocardial injury and final infarct size,
independently of other variables. Accordingly, we have
evaluated time dependent changes of IR in relation to
myocardial reperfusion, CMF and final infarct size in
non-diabetic STEMI patients treated by pPCI. We have
defined coronary flow reserve (CFR), a marker of CMF, as
a primary end-point. The residual ST-segment elevation
(ST-E) and final infarct size were secondary endpoints.
The HOMA index is a simple and inexpensive marker
of IR primary used in chronic states. It was recently vali-
dated against euglycemic hyperinsulinemic clamp in STEMI
patients as feasible for assessing IR during myocardial
infarction [32] and therefore used in the current study.Methods
Patient population
The inclusion criteria for this prospective, single center,
observational study included recanalization of left anterior
descending artery (LAD) with visually assessed residual
stenosis < 30%. The STEMI was defined and treated
according to ESC guidelines [1]. Diabetes mellitus was
defined according to the American Diabetes Association
criteria [33] and patients without previously known
diabetes but with HbA1c >6.5% on admission were not
included. The exclusion criteria also included: (1) inability
or refusal to obtain written informed consent; (2) inability
to perform echocardiography examination with coronary
flow reserve (CFR) measurements with adenosine due to
hemodynamic instability, technically poor acoustic window
precluding satisfactory imaging of the left ventricle (LV) or
LAD flow by Doppler, or states known as contraindications
for adenosine administration (chronic obstructive pulmon-
ary disease, 2nd or 3rd AV blocks); (3) significant valvular
disease, (4) temporary or permanent pacemaker and left
bundle branch block precluding ECG analysis, (5) acute or
chronic infection, (6) a history of autoimmune, malignant,
liver, kidney or thyroid diseases. The Ethical committee of
our hospital approved the study protocol. The patients
were asked to participate in the study and to sign in-
formed consent on admission to the hospital, before pPCI.
Anthropometric parameters including weight and height
were measured for all patients, and their body mass index
(BMI) was calculated as ratio of weight to height squared.
Hypertension was defined as systolic blood pressure ≥
140 mmHg, a diastolic blood pressure ≥ 90 mmHg, or use
of antihypertensive treatment. Patients were considered
smokers if they smoked ≥ 1 cigarette/day at the time of
admission or in the preceding 12 months. The Killip
class, depending on the clinical manifestation of cardiac
failure, was assessed on admission (Killip 1, no heart failure;
Killip 2, S3 and/or basal lung crepitations; Killip 3, acute
pulmonary edema; Killip 4, cardiac shock).
Blood sampling and biochemical analysis
When a diagnosis of STEMI was established and a decision
to perform pPCI was made, blood samples were obtained
from a peripheral vein before starting intervention and after
admission to the intensive coronary care unit every 6 h
during the first 48 h and every 12 h during the rest of the
stay in the intensive coronary care unit. Blood samples for
troponin I (TnI), MB fraction of creatine kinase (CK-MB),
N-terminal pro-brain natriuretic peptide (NT-proBNP),
and high-sensitive C-reactive protein (hs-CRP) determin-
ation were allowed to coagulate at room temperature for
30 min, and then centrifuged at 4000 rpm for 10 min to
obtain serum samples. Serum TnI and CK-MB were mea-
sured by chemiluminescent microparticle immunoassay
(CMIA) on Architect i2000 System. The serum levels of
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mated analyzer (Roche Diagnostics, Mannheim, Germany).
The serum hs-CRP concentrations were measured by
means of the immunoturbidimetric test (Olympus Life and
Material Science Europe GmbH, Ireland) on an Olympus
AU 400 analyzer. The lowest detectable level was 0.02 mg/L.
Serum insulin was measured using a chemiluminescent
microparticle immunoassay on an Architect i2000SR in-
strument (Abbott Diagnostics, Wiesbaden, Germany).
According to the manufacturer’s package insert, Architect
Insulin assay has a measurement range of 1–300 μU/mL
with analytical sensitivity ≤ 1.0 μU/mL. Other biochemical
and hematologic measurements involved the use of stand-
ard assays. The peak values for CK-MB, Tn I, NT-proBNP
and hs-CRP were considered for further analysis and for
other biochemical parameters 2nd day values were used for
analysis, because CFR was measured on the 2nd day. The
HOMA was calculated on the 2nd and 7th day according to
the following formula: (fasting insulin [µU/mL] × fast-
ing glucose [mmol/L])/22.5. Patients whose values
exceeded the sex-specific 75th percentile (i.e., 1.80 for
women and 2.12 for men) were considered to have
HOMA-IR according to guidelines proposed by the
European Group for the study of Insulin Resistance (EGIR)
[34]. The estimated glomerular filtration rate (eGFR) was
calculated using abbreviated Modification of Diet in Renal
Disease study formula [35].
Primary PCI
PCI was performed within 12 h from the onset of chest
pain by experienced interventionists. Coronary angiography
was performed as quickly as possible. Collateral flow from
the patent vessels to the infarct-related artery was graded
using the classification developed by Rentrop [36]. In all
patients, a stent was successfully implanted in the LAD.
Angiographic Thrombolysis In Myocardial Infarction
(TIMI) flow grade was evaluated as described previously
[37]. Slow/no-reflow was defined as TIMI ≤ 2 after PCI.
All patients and their angiograms were graded according
to the number of diseased coronary arteries. A coronary
artery was considered diseased if there was any obstructive
lesion ≥ 70% in diameter in that artery or one of its major
branches (diameter ≥2.5 mm). Medication used in the
acute phase included loading a dose of clopidogrel 600 mg
and aspirin 300 mg and intravenous bolus of heparin be-
fore pPCI, followed by dual antiplatelet therapy (clopido-
grel or ticlopidine and aspirin) and statins in all patients.
ACE-I/ARB, beta blockers, diuretics, digitalis and calcium
antagonist were used in 82%, 96%, 52%, 9%, 9%, respect-
ively. Glicoprotein IIb/IIIa inhibitor, thrombectomy and
intracoronary vasodilatators were administered at the dis-
cretion of the interventional cardiologist. In the current
study 24% of patients had thiazide diuretics in therapy and
98% of patients had statins from the 3rd day after pPCI.None of the patients included in the current study
reached the glycaemic threshold of 11 mmol/l to get
insulin.
Outcome variables
CMF estimated by coronary flow reserve (CFR) was
defined as a primary endpoint. Myocardial perfusion,
assessed by the residual ST-E, and infarct size, evaluated
by the fixed perfusion defect on SPECT-MPI, were defined
as secondary endpoints.
Electrocardiogram (ECG) measurements
The degree of myocardial reperfusion in this study was
assessed by ECG ST-segment recovery, because it has
strong power for predicting death, heart failure or shock
up to 90 days after STEMI [37]. A standard 12-lead ECG
was recorded at baseline and ≈ 30 minutes after pPCI. All
ECG records were magnified and ST-E was measured at
the J point to the nearest 0.05 mV. The person performed
ECG measurement was blinded to other clinical and
laboratory data. In the current study, we used a simple
ST-segment- recovery method of residual ST-E measured
in the most affected lead on the post-PCI ECG, since
this method was previously shown to perform as well as
complex ones in predicting outcomes after primary PCI
in STEMI [38].
Transthoracic echocardiographic examination with the
CFR evaluation
CMF in this study was assessed by transthoracic echo-
cardiography and CFR of the infarct, i.e. the left anterior
descending coronary artery (LAD), since this method is
noninvasive, reliable and validated for CMF assessment
in post pPCI patients [39-41]. It was performed on the
2nd day after pPCI using a commercially available ultra-
sound machine (Acuson Sequa C 256, Siemens, Medical
Solutions, USA) and a 3V2C multifrequency transducer
using second harmonic technology. Echocardiography
included conventional resting 2D examination with mea-
surements of LV end-diastolic and end-systolic volumes (LV
EDV and LV ESV) and ejection fraction (EF) by Simpson’s
methods, and evaluation of LAD CFR as previously
described [39-41]. In short, color Doppler detection of the
LAD flow was obtained by a modified apical approach
using a 4-MHz transducer, with Doppler mapping velocity
range set between 16 to 24 cm/sec. The systolic and
diastolic coronary flow velocity spectrum was obtained
at baseline and during the peak of hyperemia induced
by i.v. adenosine (0.14 mg/kg/min during 1 minute).
CFR was calculated as the ratio of hyperemic to basal
peak diastolic flow velocities. All studies were digitally
recorded and stored for off-line analysis by two experi-
enced examiners blinded to patient clinical data. The
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measurements in our laboratory is <10% [40].
SPECT-MPI
Gated single-photon emission computed tomography myo-
cardial perfusion imaging (SPECT-MPI) with 99 m-techne-
tium metoxy-isobutile-isonitrile (99mTc-MIBI) was done
6 weeks after pPCI to define the final infarct size (percent-
age of myocardium with fixed perfusion abnormalities) by
the person blinded to other clinical and laboratory data.
740 MBq of 99mTc-MIBI was injected 10–15 minutes
after sublingual administration of 0.5 mg nitroglycerin
coinciding with the peak hemodynamic response. The
acquisition was performed 45–60 minutes after the injec-
tion. Gated SPECT-MPI data were acquired in the supine
position with a single head SPECT gamma camera
(Siemens, e.cam) equipped with a high-resolution low
energy collimator. Sixty-four projection images were re-
corded over a 180° semicircular orbit extending from the
45° right anterior oblique position to the 45° left posterior
oblique position, with matrix size 64 × 64, zoom 1.45, and
gating 8 frames per cardiac cycle. Using the e.soft com-
mercial software, transaxial tomograms were generated
from gated projection data, reconstructed with a fil-
tered back-projected algorithm, and reoriented to ob-
tain oblique-angle tomograms parallel to the long and
short axes of the left ventricle. The reconstructed data
were projected as myocardial tomographic slices in
short-axis, vertical-long, and horizontal-long axis views.
The 4D-MSPECT software was then used for semiquanti-
tative evaluation of myocardial perfusion and function. The
extent of myocardial perfusion abnormalities (%) was
expressed relative to the left ventricle, based on polar
maps. A large infarction was defined as SPECT-MPI
perfusion abnormality >20%.
Statistical analysis
Continuous variables were tested for normal distribution
using the Kolmogorov-Smirnov test. Normally distributed
continuous variables are expressed with mean ± SD, and
continuous variables that did not show a normal distribu-
tion are expressed as the median value and interquartile
range (IQR: 25th, 75th percentile). CFR was analyzed both
as continuous variable (with normal distribution) and
as categorical, with values ≥ 2 considered as normal.
Worst residual ST-E was analyzed as categorical (<1 mm,
1 to <2 mm, and ≥ 2 mm). SPECT-MPI perfusion defect
was analyzed as a continuous variable (without normal
distribution) and categorical (>20% and ≤20%). Categorical
data are shown as frequencies and percentages. For com-
parison between HOMA the positive vs. negative group
student t-test, the χ2 test and the independent-samples
Mann–Whitney U test were used. To account for multiple
testing, Bonferroni’s correction was applied. Spearman’srank correlation coefficients were used to assess the rela-
tionships between HOMA and other variables. Univariate
and multivariate (backward Wald) binary logistic re-
gression analysis were used to evaluate the relation-
ship between outcome variables (residual ST-E ≥2 mm,
CFR <2 and SPECT-MPI perfusion defect >20%) and
potential determinants including the HOMA index. Re-
sults are expressed as the odd ratios (ORs) and their
95% confidence intervals (CI) per one standard deviation
increment of each measure (facilitating comparisons of
effect sizes for individual measures). The statistical
analyses were performed using SPSS (SPSS version 20.0
Inc., Chicago). Statistical significance was defined as
p < 0.05.
Results
A total of 108 non-diabetic consecutive patients with first
anterior STEMI treated by pPCI were initially screened
for the study during the period from November 2009 to
June 2010. Out of 108 initially screened patients 3 patients
died before they completed the study and 1 was excluded
due to poor acoustic window. The final study population
included 104 patients. The SPECT-MPI studies were done
in the subgroup of 61 patients who agreed to be examined
and were able to come for this examination 6 weeks after
pPCI. The incidence of HOMA index positivity was simi-
lar to that in the entire study group.
The median age in the study population was 57 years
(IQR: 48–66) and 71% were male. They were mainly non
smokers (67%), hypertensive (62%), had hypercholester-
olemia (46%) and 65% had BMI >25 kg/m2. The median
time from symptom onset to pPCI was 4 h.
Patient’s clinical and laboratory characteristics according
to HOMA index positivity (i.e. IR) on day 2 and day 7 are
listed in Tables 1, 2, 3 and 4.
In the whole study group the HOMA index increased
from day 2 (median 1.94; IQR: 1.42-2.85) to day 7 (median
2.33; IQR: 1.60-3.61) (p < 0.001), mainly due to the signifi-
cant increment in insulin concentration. It increased from
a median value of 8.37 IU/L (IQR: 6.63-11.65) on day 2
to a median value of 9.83 IU/L (IQR: 7.72-15.77) on day
7 (p < 0.001). Glycaemia was similar on day 2 (median
5.3; IQR 4.9-5.9 mmol/L) and day 7 (median 5.3; IQR:
4.9-5.8 mmol/L) (p = ns). According to EGIR (European
Group for Insulin Resistance) criteria, 57 out of 104
patients (55%) had IR on the 2nd day and 60 out of 104
patients (58%) had IR on the 7th day.
Relationship between insulin resistance and coronary
microcirculatory function
CFR after pPCI was significantly lower in patients with
IR based on the HOMA index both on the 2nd (Table 5)
and 7th day (Table 6) (p = 0.002, for both). In HOMA
index positive groups, both on day 2 and day 7 there
Table 1 Patients’ characteristics according to the 2nd day HOMA positivity
2nd day HOMA index positive 2nd day HOMA index negative p value
n, (%) 57/104 (55) 47/104 (45)
Age Median (IQR) 59 (50–68) 54 (48–64) 0.150
Male n (%) 38 (66) 36 (77) 0.266
BMI (kg/m2) Median (IQR) 25.2 (23.9-28.4) 25.9 (23.6-26.7) 0.809
Hypertension n (%) 37 (65) 27 (57) 0.436
Hypercholesterolemia n (%) 29 (51) 19 (40) 0.289
Smokers n (%) 18 (32) 16 (34) 0.790
Symptom onset to pPCI (min) Median (IQR) 257 (160–300) 210 (143–300) 0.156
Killip class on admission 1/2/3 n (%) 32/20/5 (56/35/9) 31/13/3 (66/28/6) 0.592
Heart rate (bpm) Median (IQR) 81 (73–94) 74 (65–81) 0.010a
Angiographic findings
Infarct related artery LAD n (%) 57 (100) 47 (100) ns
Multi vessel disease n (%) 22 (39) 16 (34) 0.631
Initial (pre-stenting) TIMI flow 0/1/2/3 n (%) 46/8/1/2 (80/14/2/4) 38/2/5/2 (81/4/11/4) 0.106
Location of culprit lesion, proximal/mid/distal LAD n (%) 24/33/0 (42/58/0) 27/20/0 (57/43/0) 0.119
Rentrop grade, 0/1/2-3 n (%) 34/10/3 (73/21/6) 50/7/0 (88/12/0) 0.059
Procedural data
No of the implanted stents Median (IQR) 1 (1–1) 1 (1–2) 0.154
Bare metal stent n (%) 45 (79) 35 (75) 0.589
Final minimal stent diameter (mm) Median (IQR) 2.9 (2.7-3.0) 2.8 (2.7-3.0) 0.910
Post-procedural data
Slow/no reflow after pPCI n (%) 9 (16) 3 (6) 0.135
Echocardiography
LV EDV (ml) Mean ± SD 112.5 ± 37.9 111.6 ± 36.1 0.903
LV ESV (ml) Mean ± SD 58.9 ± 28.4 56.7 ± 25.5 0.684
LV EF (%) Mean ± SD 49.8 ± 10.0 50.2 ± 10.5 0.846
IR, interquartile range; BMI, body mass index; pPCI, primary percutaneous coronary intervention; bpm, beat per minute; LAD, left anterior descending artery; TIMI,
Thrombolysis in Myocardial Infarction; LV left ventricle; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; SD, standard deviation.
aOn the basis of Bonferroni’s correction, a p-value less than 0.025 indicates statistical significance.
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CFR < 2).
CFR significantly correlated with both HOMA indi-
ces (for 2nd day HOMA: r = −0.386 and for 7th HOMA:
r = −0.331, p < 0.001) (Figure 1). CFR correlated also with
2nd day glycaemia (r = −0.238, p = 0.015) and 2nd day insuli-
nemia (r = −0.297, p = 0.002). CFR did not correlate with
HbA1c (r = 0.007, p = 0.941), weakly correlated with gly-
caemia on admission (r =−0.187, p = 0.054) and did not cor-
relate with insulinemia on admission (r = 0.007, p = 0.946).
In multivariable model 2nd day HOMA was an inde-
pendent predictor of impaired CFR after adjustment for
significant univariate predictors (heart rate, TnI peak,
hsCRP), previously shown predictors of myocardial re-
perfusion (time from symptom onset to pPCI, glucose
on admission, NT-proBNP) and potential cofounding
variables for IR (age, gender and BMI), with OR of 5.98
(95% CI 1.88-19.03, p = 0.002).Relationship between insulin resistance and degree of
myocardial reperfusion
The residual ST-E ≥ 2 mm on post-procedural ECG was
significantly more frequent among patients with IR com-
pared to those without IR, both on day 2 (Table 5) and day
7 (Table 6).
The 2nd day HOMA index remained independently
associated with residual ST-E ≥2 mm in multivariable
analysis adjusted for significant univariate ST-E predictors
(BMI and age), potential confounding variables for IR
(gender) and previously shown predictors of myocardial
reperfusion after primary PCI (time from symptom onset
to pPCI, glycaemia on admission), with the OR of 11.70
(95% CI 2.46-55.51, p = 0.002).
Relationship between insulin resistance and final infarct size
In 66 out of 104 patients SPECT-MPI was done to as-
sess the final infarct size 6 weeks after pPCI. Patients
Table 2 Patients’ characteristics according to the 7th day HOMA positivity
7th day HOMA index positive 7th day HOMA index negative p
n (%) 60/104 (58) 44/104 (42)
Age Median (IQR) 60 (49–67) 51 (45–62) 0.117
Male n (%) 42 (70) 32 (73) 0.762
BMI (kg/m2) Median (IQR) 25.8 (25.0-28.7) 24.7 (22.1-26.6) 0.010a
Hypertension n (%) 38 (63) 26 (59) 0.660
Hypercholesterolemia n (%) 26 (43) 22 (50) 0.500
Smokers n (%) 19 (32) 15 (34) 0.795
Symptom onset to pPCI (min) Median (IQR) 250 (180–330) 185 (135–300) 0.031a
Killip class on admission 1/2/3/4 n (%) 32/23/5 (54/38/8) 31/10/3 (71/23/6 0.197
Heart rate (bpm) Median (IQR) 80 (68–92) 78 (65–85) 0.010a
Angiographic findings
Infarct related artery LAD n (%) 60 (100) 44 (100) ns
Multi vessel disease n (%) 26 (43) 12 (27) 0.093
Initial (pre-stenting) TIMI flow 0/1/2/3 n (%) 50/4/2/4 (83/7/3/7) 34/6/4/0 (77/14/9/0) 0.122
Location of culprit lesion (proximal/mid/distal LAD) 29/31/0 (48/52/0) 22/22/0 (50/50/0) 0.867
Rentrop grade 0/1/2-3 n (%) 45/11/4 (75/19/6) 37/7/0 (85/15/0) 0.2193
Procedural data
No of the implanted stents Median (IQR) 1 (1–2) 1 (1–2) 0.863
Bare metal stent n (%) 44 (73) 36 (82) 0.310
Final minimal stent diameter (mm) Median (IQR) 2.9 (2.7-3.1) 2.8 (2.7-3.0) 0.744
Post-procedural data
Slow/no reflow after pPCI n (%) 10 (17) 2 (5) 0.056
Echocardiography
LV EDV (ml) Mean ± SD 117.2 ± 35.2 105.1 ± 38.4 0.100
LV ESV (ml) Mean ± SD 63.5 ± 26.3 50.4 ± 26.4 0.014a
LV EF (%) Mean ± SD 47.4 ± 8.4 53.4 ± 11.4 0.003a
IQR, interquartile range; BMI, body mass index; pPCI, primary percutaneous coronary intervention; bpm, beat per minute; LAD, left anterior descending artery; TIMI,
Thrombolysis in Myocardial Infarction; LV left ventricle; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; SD, standard deviation.
aOn the basis of Bonferroni’s correction, a p-value less than 0.025 indicates statistical significance.
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had a larger perfusion defect compared to patients
without IR (p = 0.027), however the difference was of
borderline statistical significance when Bonferroni’s
correction was applied (Table 6). SPECT-MPI perfu-
sion defect correlated with 7th day HOMA index (r =
0.331, p = 0.008), but not with the 2nd day HOMA
index.
In the multivariable model the 7th day HOMA index
was an independent predictor of a large infarction
(i.e., perfusion defect >20%) after adjustment for sig-
nificant univariate predictors (TnI peak, time form
symptom onset to pPCI), previously shown predictors
of myocardial reperfusion (glucose level on admission)
and potential cofounding variables for IR (age, gender
and BMI) with OR of 11.37 (95% CI 1.34-96.21, p =
0.026).Correlations between HOMA indices with biochemical and
clinical parameters
The HOMA index on day 2 correlated with the HOMA
index on day 7 (r = 0.406, p < 0.001). The second day
HOMA index significantly correlated with heart rate
(r = 0.354, p < 0.001), peak values of hs-CRP (r = 0.205,
p = 0.037), NT-proBNP (r = 0.230, p = 0.02) and Tn I (r =
0.258, p = 0.009). The seventh day HOMA index was sig-
nificantly associated with heart rate (r = 0.205, p = 0.02),
left ventricular ejection fraction (r = −0.241, p = 0.02), BMI
(r = 0.231, p = 0.019) and peak values of hs-CRP (r = 0.290,
p = 0.003), NT-proBNP (r = 0.321, p = 0.001) and Tn I
(r = 0.235, p = 0.017).
Discussion
The present study analyzed IR in the acute phase of
STEMI in non-diabetic patients treated by pPCI. First,
Table 3 Patients’ laboratory data according to the 2nd day HOMA index positivity
2nd day HOMA index positive (N = 57) 2nd day HOMA index negative (N = 47) p
Glucose (mmol/L)
admission 7.8 (6.6-9.0) 7.6 (6.4-9.4) 0.667
2nd day 5.7 (5.2-6.3) 4.9 (4.5-5.3) <0.001a
7th day 5.5 (4.9-5.9) 5.2 (4.9-5.6) 0.042
Insulin (IU/L)
admission 18.82 (8.55-23.77) 11.29 (7.24-17.00) 0.009a
2nd day 11.32 (8.88-13.52) 6.59 (4.78-7.50) <0.00 1a
7th day 10.81 (8.42-19.65) 8.80 (7.0-11.52) <0.001a
HOMA index
2nd day 2.76 (2.21-3.42) 1.34 (1.04-1.69) <0.001a
7th day 2.75 (1.93-4.17) 2.04 (1.45-2.92) <0.001a
HbA1c (%) 5.6 (5.4-5.8) 5.5 (5.3-5.7) 0.063
WBC count on admission (×109/L) 12.7 (9.7-16.2) 12.6 (9.9-13.4) 0.739
hs-CRP (mg/L) 52.6 (19.9-123.7) 50.0 (22.3-108.8) 0.615
TnI (μg/L) 134.20 (48.38-165.00) 106.80 (79.84-190.17) 0.171
NT-proBNP (pg/mL) 2165 (1176–4693) 2099 (650–4133) 0.227
Total-C (mmol/L) 5. 22(4.40-6.03) 4.82 (4.53-5.68) 0.724
HDL-C (mmol/L) 1.08 (0.92-1.21) 1.16 (0.99-1.35) 0.825
LDL-C (mmol/L) 3.20 (2.65-3.80) 3.16 (2.91-3.69) 0.666
Apo A1 (g/L) 1.24 (1.11-1.36) 1.38 (1.15-1.53) 0.006a
Apo B (g/L) 1.00 (0.86-1.17) 0.98 (0.85-1.11) 0.418
TG (mmol/L) 1.60 (1.22-2.17) 1.45 (1.20-1.74) 0.138
Uric acid (μmol/L) 280 (231–332) 277 (209–329) 0.518
eGFR (mL/min per 1.73 m2) 89.06 ± 22.63 85.24 ± 23.05 0.398
Data are presented as median (interquartile range), except eGFR that is presented as mean ± standard deviation.
aOn the basis of Bonferroni’s correction, a p-value less than 0.025 indicates statistical significance.
Abbreviations: HOMA Homeostatic Model Assessment, HbA1c hemoglobin A1c, WBC white blood cells, hs-CRP high sensitive C-reactive protein, TnI troponin I,
NTproBNP N-terminal pro-brain natriuretic peptide, Total-C Total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol,
Apo apolipoprotein, TG triglycerides, eGFR estimated glomerular filtration rate, SD standard deviation.
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common even in non-diabetic patients and changeable.
Second, IR was related to the degree of myocardial reper-
fusion and correlated well with the CMF after mechanical
revascularization, independently of other variables. Third,
IR at the end of the first week after pPCI was an inde-
pendent predictor of the final infarct size.
IR in the acute phase of STEMI is predominately part
of acute glycometabolic response to stress [22]. The term
acute IR implies its presence during acute (early) phase
of STEMI. Although we included only patients without
diabetes mellitus, we cannot strictly exclude the presence
of IR before and/or after the first STEMI week, since
evaluation of IR status was not done before or after this
period. Generally, in critically ill patients acute IR is
related to more severe acute illness and warrants poor
clinical outcome [42,43]. By traditional concept, acute
IR is induced by acute stress, with a small possibility
to be further directly involved in the development oraggravation of acute illness. However, recent studies
[18-21] challenge this concept to a certain extent.
Few studies have analyzed time dependent changes of
acute IR and/or insulin sensitivity and have related it to
clinical outcomes [22,43]. Nishio et al. [22] performed
serial HOMA index measurements among patients going
to pPCI and identified those with transient IR, in whom
HOMA index correlated with stress hormones and pa-
tients with persistent IR, in whom HOMA index during
the 4 months follow-up correlated with leptin and con-
tributed to stent restenosis. In the current study acute IR
was present in 55% of patients on the 2nd day and in 58%
of patients on the 7th day. The HOMA index slightly, but
statistically significantly increased from day 2 to day 7,
mainly due to the increment in insulin concentration.
Similar increment in insulinemia in the early post PCI
period in non-diabetic patients was previously reported
[44]. The potential mechanisms are not clear. Effects
of prolonged cardiovascular (hemodynamic) stress and
Table 4 Patients’ laboratory data according to the 7th day HOMA index positivity
7th day HOMA index positive (N = 60) 7th day HOMA index negative (N = 44) p
Glucose (mmol/L)
admission 7.9 (6.6-9.7) 7.6 (6.1-9.1) 0.134
2nd day 5.6 (5.1-5.9) 4.9 (4.6-5.3) <0.001a
7th day 5.6 (5.2-5.9) 4.9 (4.8-5.3) <0.001a
Insulin (IU/L)
admission 12.37 (9.21-21.82) 10.53 (7.45-18.43) 0.056
2nd day 8.70 (7.26-12.28) 7.56 (5.14-10.10) 0.017a
7th day 14.52 (10.69-20.15) 7.28 (6.06-8.33) <0.001a
HOMA index 5.5 (5.4-5.8)
2nd day 2.27 (1.76-2.98) 1.55 (1.09-2.28) 0.001a
7th day 3.24 (2.54-4.19) 1.51 (1.21-1.83) <0.001a
HbA1c (%) 5.5 (5.4-5.8) 5.6 (5.3-5.8) 0.801
WBC count on admission (×109/L) 12.7 (10.0-16.2) 12.6 (9.7-13.2) 0.246
hs-CRP (mg/L) 57.3 (27.3-113.3) 38.1 (22.0-76.7) 0.030
TnI (μg/L) 135.86 (85.11-182.00) 78.36 (59.04-148.63) 0.019a
NT-proBNP (pg/mL) 2777 (1702–4693) 1157 (496–4150) 0.010a
Total-C (mmol/L) 4.24 (3.77-4.67) 4.26 (3.83-5.04) 0.613
HDL-C (mmol/L) 0.83 (0.70-0.99) 0.93 (0.82-1.12) 0.011a
LDL-C (mmol/L) 2.67 (2.39-3.09) 2.70 (2.21-3.47) 0.795
Apo A1 (g/L) 1.10 (0.96-1.30) 1.18 (1.10-1.25) 0.037a
Apo B (g/L) 0.85 (0.75-0.94) 0.90 (0.79-0.94) 0.481
TG (mmol/L) 1.39(1.11-1.85) 1.23 (0.97-1.64) 0.129
Uric acid (μmol/L) 273 (223–310) 279 (237–329) 0.703
eGFR (mL/min per 1.73 m2) 89.09 ± 25.23 84.95 ± 19.00 0.342
Data are presented as median (interquartile range), except eGFR that is presented as mean ± standard deviation.
aOn the basis of Bonferroni’s correction, a p-value less than 0.025 indicates statistical significance.
Abbreviations: HOMA Homeostatic Model Assessment, HbA1c hemoglobin A1c, WBC white blood cells, hs-CRP high sensitive C-reactive protein, TnI troponin I,
NTproBNP N-terminal pro-brain natriuretic peptide, Total-C Total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol,
Apo apolipoprotein, TG triglycerides, eGFR estimated glomerular filtration rate, SD standard deviation.
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[44]. In our study the 7th day HOMA index correlated
better than the 2nd day HOMA index with the peak
values of NT-proBNP and hs-CRP. Nutritional status
might also influence the IR increment. In our study the
majority of patients were on regular nutrition on the 7th
day as opposed to the 2nd day, with a higher fat intake and
potentially higher free fatty acids effects on the insulin
sensitivity [45,46]. However, a comprehensive nutrition
data analysis was not done. The effect of drugs should not
be neglected, including those of thiazide diuretics, beta
blockers and some statins [47-49], reported to have poten-
tial impact on insulin sensitivity. However, in the current
study we could not find significant differences between
HOMA positive and HOMA negative patients regarding
the drug regime. None of the patients reached the gly-
caemic threshold of 11 mmol/l to get insulin.
One of the main findings in the current study is that
acute IR was related to more impaired CMF after pPCI,independently of other potential covariates. CFR is a sensi-
tive parameter of CMF. CMF after STEMI is important
for the clinical outcome independently of epicardial flow
[50]. Although the inverse relationship between HOMA
index and CFR was described in different states [51-53], to
the best of our knowledge the current study is the first to
link acute IR assessed by the HOMA index and CFR in
non-diabetic STEMI patients. Acute hyperglycemia per se
predicted impaired epicardial flow before pPCI [54] and
impaired CMF after pPCI in unselected, mixed diabetic
and non-diabetic patients [55]. It is related to increased
oxidative stress in STEMI, increases vascular cell apop-
tosis and induces acute endothelial dysfunction [56,24,57].
Insulin is under healthy condition coronary vasodilatator
and in the dose-dependent manner increases myocardial
blood flow [58,59]. However, these effects are abolished
in chronic, obesity related IR [60,61]. Only one study
evaluated acute insulinemia and coronary flow in acute cor-
onary syndrome. In 60 patients admitted to the emergency
Figure 1 Relationship between 2nd day HOMA index and
coronary microcirculatory function, assessed as coronary flow
reserve after pPCI.







ECG (n = 104) (n = 57) (n = 47)
Worst residual ST-E 0.001a
< 1 mm, n (%) 9 (16) 18 (38)
1–2 mm, n (%) 6 (10) 11 (24)
≥ 2 mm, n (%) 42 (74) 18 (38)
Echocardiography (n = 104) (n = 57) (n = 47)
CFR, mean ± SD 1.71 ± 0.36 1.93 ± 0.37 0.002a
CFR < 2, n (%) 47 (83) 23 (49) <0.001a
SPECT-MPI (n = 66) (n = 36) (n = 30)
Perfusion defect, %, (IQR) 38 (7–41) 29 (4–48) 0.957
HOMA, Homeostatic Model Assessment; ECG, electrocardiogram; ST-E, ST segment
elevation; CFR, Coronary Flow Reserve; SD, standard deviation; SPECT-MPI,
single-photon emission computed tomography myocardial perfusion image;
IQR, interquartile range.
aOn the basis of Bonferroni’s correction, a p-value less than 0.025 indicates
statistical significance.
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http://www.cardiab.com/content/13/1/73department for suspected acute coronary syndrome acute
hyperinsulinemia was present in half of them, and closely
correlated with TIMI coronary flow score [31]. In the
current study CFR better correlated to the HOMA index
than to acute glycaemia and/or insulinemia and in the
multivariable model including admission glycaemia, the
HOMA index remained an independent CFR predictor.
These data might suggest that acute IR as a phenomenon
per se could be related to the development of CMF im-







ECG (n = 104) (n = 60) (n = 44)
Worst residual ST-E <0.001a
< 1 mm, n (%) 6 (10) 21 (48)
1–2 mm, n (%) 13 (22) 3 (7)
≥ 2 mm, n (%) 41 (68) 20 (45)
Echocardiography (n = 104) (n = 60) (n = 44)
CFR, mean ± SD 1.71 ± 0.39 1.95 ± 10.33 0.002a
CFR < 2, n (%) 48 (80) 22 (50) 0.001a
SPECT-MPI (n = 66) (n = 37) (n = 29)
Perfusion defect, %,
median (IQR)
39 (32–50) 20 (0–43) 0.027
HOMA, Homeostatic Model Assessment; ECG, electrocardiogram; ST-E, ST segment
elevation; CFR, Coronary Flow Reserve; SD, standard deviation; SPECT-MPI,
single-photon emission computed tomography myocardial perfusion image;
IQR, interquartile range.
aOn the basis of Bonferroni’s correction, a p-value less than 0.025 indicates
statistical significance.The relationship between acute IR and ST-E resolution
was not previously evaluated. Acute hyperglycemia was
related to limited ST-E recovery in mixed diabetic and
non-diabetic STEMI population after thrombolytic ther-
apy [62] and after pPCI [63]. Metabolic syndrome (chronic
IR) was a predictor of ST-E resolution after pPCI [11]. In
the current study in patients without diabetes, incomplete
ST-E resolution was significantly more frequent among
those with acute IR. However, only the 2nd day HOMA
index was independently associated with the residual
ST-E.
The relationship between acute IR in non-diabetic
STEMI patients and myocardial damage in terms of
peak enzymes was previously reported [18,19]. In our
study both HOMA indices correlated well with the
peak TnI. However, only the 7th day HOMA index was
an independent predictor of the final infarct size on
SPECT-MPI. It could be speculated that prolonged IR
during acute phase is important. Furthermore, the 7th
day HOMA index might not only be a part of acute gly-
colmetabolic response to stress, but also part of chronic or
prolonged intermittent IR that might influence formation
of final infarct size in the following weeks after STEMI.
From the clinical standpoint, in the current study
HOMA index on day 2 better correlated with myocardial
reperfusion, both HOMA indices well correlated with
the CMF, whereas HOMA index on day 7 predicted final
infarct size. Both data might be clinically valuable: HOMA
index on day 2 for the in-hospital course, HOMA index
on day 7 for the long-term processes such as formation of
the final infarct size. Although our data do not unambigu-
ously demonstrate cause and effect relationship between
acute IR and CMF, they strengthen the need for attention
to be paid to IR during and after STEMI. Taking in mind
that IR could be potentially modified, its regulation might
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afterwards.
Study limitations
Study results should be interpreted with some limitations.
First, our study is a single centre experience with a rela-
tively small sample size. Second, CMF was measured by
echocardiography without invasive or magnetic resonance
imaging. However, this approach has been previously vali-
dated in our laboratory or elsewhere [39-41] and com-
pared to positron emission tomography imaging [39].
Third, IR assessment was based on the HOMA index and
EGIR classification, which was primarily defined for chronic
states. Whether different cut-offs for acute IR should
be used in the acute phase of myocardial infarction, as
suggested by some authors [21], remains an open question.
In the current study the “area at risk” was not determined
by SPECT-MPI. However, there were no significant differ-
ences between patients with IR vs. without IR regarding the
infarct related artery, the position of the culprit lesion and
collateral circulation.
Conclusion
In conclusion, our results suggest that acute IR after pPCI
in non-diabetic STEMI patients is related to impaired
myocardial reperfusion, impaired CMF and potentially to
a larger final infarct size.
Abbreviations
IR: Insulin resistance; STEMI: ST segment elevation myocardial infarction;
HOMA: Homeostatic model assessment; pPCI: Primary percutaneous coronary
intervention; CMF: Coronary microcirculatory function; LAD: Left anterior
descending artery; HbA1c: Hemoglobin A1c; CFR: Coronary flow reserve;
LV: Left ventricle; TnI: Troponin I; NT-proBNP: N-terminal pro-brain natriuretic
peptide; hs-CRP: High-sensitive C-reactive protein; eGFR: Estimated glomerular
filtration rate; TIMI: Thrombolysis in myocardial infarction; ST-E: ST segment
elevation; SPECT-MPI: Single-photon emission computed tomography
myocardial perfusion image; LV EDV: Left ventricular end diastolic volume; LV
ESV: Left ventricular end systolic volume; LV EF: Left ventricular ejection fraction;
IQR: Interquartile range; OR: Odd ratio; CI: Confidence interval; WBC: White
blood cells; HDL: High-density lipoprotein; LDL: Low-density lipoprotein;
Apo: Apolipoprotein.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
DT: conceived the study, participated in the design of the study, performed
echocardiographic and CFR examinations, helped to perform statistic analysis
and helped to write the manuscript. SS: carried out laboratory analysis and
helped to write the manuscript. DSS: carried out SPECT-MPI analysis and
helped to write the manuscript. MP: helped in ECG analysis. BB carried out
cath lab work, angiographic analysis, and reviewed the manuscript. MB helped
in echocardiographic examinations and cat lab work. JM participated in the
design of the study, performed statistical analysis. DO performed cath lab work
and angiographic analysis. BVT supervised echocardiographic examinations. MP
performed echocardiographic examination. IN: performed echocardiographic
examination. JS: participated in the design of the study. ADD: helped in CFR
measurements. MT: helped in CFR measurements. ND: helped to carry out
laboratory analysis. OP: performed echocardiographic examination and CFR
measurements. OV: helped in ECG analysis. EN: helped in echocardiographic
examination. JK: carried out cath lab work and angiographic analysis. AR: helpedin coordination. MO: participated in the design of the study. All authors read
and approved the final manuscript.Acknowledgement
This study is part of the projects organized by Ministry of education and
science, Republic of Serbia, No 145053, III41022 and ON 175086.
Author details
1Department of Cardiology, Clinical Centre of Serbia, Ul. Koste Todorovica 8,
11000 Belgrade, Serbia. 2School of Medicine, University of Belgrade, Belgrade,
Serbia. 3Center for Medical Biochemistry, Clinical Centre of Serbia, School of
Pharmacy, University of Belgrade, Belgrade, Serbia. 4Department of Nuclear
medicine, Clinical Centre of Serbia, Belgrade, Serbia. 5Institute of Medical
Statistics and Informatics, School of Medicine, University of Belgrade,
Belgrade, Serbia. 6Institute for Gerontology and Palliative Care, Belgrade,
Serbia. 7Serbian Academy of Sciences and Arts, University of Belgrade,
Belgrade, Serbia.
Received: 20 February 2014 Accepted: 2 April 2014
Published: 5 April 2014References
1. Task Force on the management of ST-segment elevation acute myocardial
infarction of the European Society of Cardiology (ESC): Guidelines for the
management of acute myocardial infarction in patients presenting with
ST-segment elevation. Eur Heart J 2012, 33(20):2569–2619.
2. Lerman A, Holmes DR, Herrmann J, Gersh BJ: Microcirculatory dysfunction
in ST-elevation myocardial infarction: cause, consequence, or both?
Eur Heart J 2007, 28(7):788–97.
3. Niccoli G, Burzotta F, Galiuto L, Crea F: Myocardial no-reflow in humans.
J Am Coll Cardiol 2009, 54(4):281–292.
4. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS: Insulin resistance
and the relationship of a dyslipidemia to coronary heart disease: the
Framingham Heart Study. Arterioscler Thromb Vasc Biol 2011, 31:1208–1214.
5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna
RC, Muggeo M: Insulin resistance as estimated by homeostasis model
assessment predicts incident symptomatic cardiovascular disease in
Caucasian subjects from the general population: the Bruneck study.
Diabetes Care 2007, 30:318–324.
6. Arnold SV, Lipska KJ, Li Y, Goyal A, Maddox TM, McGuire DK, Spertus JA,
Kosiborod M: The reliability and prognosis of in-hospital diagnosis of
metabolic syndrome in the setting of acute myocardial infarction. J Am
Coll Cardiol 2013, 62(8):704–708.
7. Uchida Y, Ichimiya S, Ishii H, Kanashiro M, Watanabe J, Yoshikawa D,
Takeshita K, Sakai S, Amano T, Matsubara T, Murohara T: Impact of
metabolic syndrome on various aspects of microcirculation and major
adverse cardiac events in patients with ST-segment elevation myocardial
infarction. Circ J 2012, 76(8):1972–1979.
8. Tartan Z, Ozer N, Uyarel H, Akgul O, Gul M, Cetin M, Kasikcioglu H, Cam N:
Metabolic syndrome is a predictor for an ECG sign of no-reflow after
primary PCI in patients with acute ST-elevation myocardial infarction.
Nutr Metab Cardiovasc Dis 2008, 18(6):441–447.
9. Wensley I, Salaveria K, Bulmer AC, Donner DG, du Toit EF: Myocardial
structure, function and ischaemic tolerance in a rodent model of obesity
with insulin resistance. Exp Physiol 2013, 98(11):1552–1564.
10. Bøhmer E, Seljeflot I, Arnesen H, Hoffmann P, Abdelnoor M, Halvorsen S:
The association between metabolic syndrome and infarct size in
patients with acute myocardial infarction. Scand J Clin Lab Invest 2010,
70(4):287–293.
11. Kranjcec D, Altabas V: Metabolic syndrome influencing infarct size and
heart failure in patients with acute coronary syndrome: does gender
matter? Endocr J 2012, 59(12):1065–1076.
12. Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF,
Kent KM, Suddath WO, Pichard AD, Waksman R: Metabolic syndrome in
patients with acute myocardial infarction is associated with increased
infarct size and in-hospital complications. Cardiovasc Revasc Med 2006,
7(1):7–11.
13. Reddy KJ, Singh M, Bangit JR, Batsell RR: The role of insulin resistance in
the pathogenesis of atherosclerotic cardiovascular disease: an updated
review. J Cardiovasc Med (Hagerstown) 2010, 11:633–647.
Trifunovic et al. Cardiovascular Diabetology 2014, 13:73 Page 11 of 12
http://www.cardiab.com/content/13/1/7314. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S:
Insulin resistance, the metabolic syndrome, and risk of incident
cardiovascular disease: a population-based study. J Am Coll Cardiol
2007, 49(21):2112–2119.
15. Karrowni W, Li Y, Jones PG, Cresci S, Abdallah MS, Lanfear DE, Maddox
TM, McGuire DK, Spertus JA, Horwitz PA: Insulin resistance is associated
with significant clinical atherosclerosis in nondiabetic patients with
acute myocardial infarction. Arterioscler Thromb Vasc Biol 2013,
33(9):2245–2251.
16. Cadeddu C, Nocco S, Piano D, Deidda M, Cossu E, Baroni MG, Mercuro G:
Early impairment of contractility reserve in patients with insulin
resistance in comparison with healthy subjects. Cardiovasc Diabetol 2013,
12(1):66.
17. Uetani T, Amano T, Harada K, Kitagawa K, Kunimura A, Shimbo Y, Harada K,
Yoshida T, Kato B, Kato M, Marui N, Nanki M, Hotta N, Ishii H, Matsubara T,
Murohara T: Impact of insulin resistance on post-procedural myocardial
injury and clinical outcomes in patients who underwent elective
coronary interventions with drug-eluting stents. JACC Cardiovasc Interv
2012, 5(11):1159–1167.
18. Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF: Correlates of acute
insulin resistance in the early phase of non-diabetic ST-elevation
myocardial infarction. Diab Vasc Dis Res 2011, 8(1):35–42.
19. Lazzeri C, Sori A, Chiostri M, Gensini GF, Valente S: Prognostic role of
insulin resistance as assessed by homeostatic model assessment index
in the acute phase of myocardial infarction in nondiabetic patients
submitted to percutaneous coronary intervention. Eur J Anaesthesiol 2009,
26(10):856–862.
20. Lazzeri C, Valente S, Chiostri M, Attanà P, Mattesini A, Gensini GF: Acute
insulin resistance assessed by the homeostatic model assessment in
acute coronary syndromes without previously known diabetes. Angiology
2013. [Epub ahead of print]. doi:10.1177/0003319713489018.
21. Sanjuan R, Blasco ML, Huerta R, Palacios L, Carratala A, Nunyez J, Sanchis J:
Insulin resistance and short-term mortality in patients with acute
myocardial infarction. Int J Cardiol 2014, 172(2):e269–e270.
22. Nishio K, Shigemitsu M, Kusuyama T, Fukui T, Kawamura K, Itoh S, Konno N,
Katagiri T: Insulin resistance in nondiabetic patients with acute
myocardial infarction. Cardiovasc Revasc Med 2006, 7(2):54–60.
23. Lazzeri C, Valente S, Chiostri M, Attanà P, Picariello C, Gensini GF: The
glucose dysmetabolism in the acute phase of non-diabetic ST-elevation
myocardial infarction: from insulin resistance to hyperglycemia. Acta
Diabetol 2013, 50(3):293–300.
24. Zarich WS, Nesto RW: Implications and treatment of acute hyperglycemia
in the setting of acute myocardial infarction. Circulation 2007,
115(18):e436–e439.
25. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA:
Plasma glucose at hospital admission and previous metabolic control
determine myocardial infarct size and survival in patients with and
without type 2 diabetes: the Langendreer Myocardial Infarction and
Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care
2005, 28(10):2551–2553.
26. Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K, Miyazaki S,
Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue T,
Saito F, Ogawa H, Japanese Acute Coronary Syndrome Study Investigators:
Acute hyperglycemia is associated with adverse outcome after acute
myocardial infarction in the coronary intervention era. Am Heart J 2005,
150(4):814–820.
27. Cruz-Gonzalez I, Chia S, Raffel OC, Sanchez-Ledesma M, Senatore F, Wackers
FJ, Nathan DM, Jang IK: Hyperglycemia on admission predicts larger
infarct size in patients undergoing percutaneous coronary intervention
for acute ST-elevation myocardial infarction. Diabetes Res Clin Pract 2010,
88(1):97–102.
28. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura
T, Nakamura S, Yoshida M: Impact of acute hyperglycemia on left
ventricular function after reperfusion therapy in patients with a first
anterior wall acute myocardial infarction. Am Heart J 2003,
146(4):674–678.
29. García RG, Rincón MY, Arenas WD, Silva SY, Reyes LM, Ruiz SL, Ramirez F,
Camacho PA, Luengas C, Saaibi JF, Balestrini S, Morillo C, López-Jaramillo P:
Hyperinsulinemia is a predictor of new cardiovascular events in
Colombina patients with a first myocardial infarction. Int J Cardiol 2011,
148(1):85–90.30. Kragelund C, Snorgaard O, Køber L, Bengtsson B, Ottesen M, Højberg S,
Olesen C, Kjaergaard JJ, Carlsen J, Torp-Petersen C, TRACE Study Group:
Hyperinsulinaemia is associated with increased long-term mortality
following acute myocardial infarction in non-diabetic patients. Eur Heart
J 2004, 25(21):1891–1897.
31. Panza-Nduli J, Coulic V, Willems D, Devriendt J, Gottignies P, Staroukine M,
De Bels D: Influence of blood insulin measurement in acute coronary
syndrome. Crit Pathw Cardiol 2011, 10(4):185–188.
32. Moura FA, Carvalho LS, Cintra RM, Martins NV, Figueiredo VN, Quinaglia E,
Silva JC, Almeida OL, Coelho OR, Sposito AC: Validation of surrogate
indexes of insulin sensitivity in acute phase of myocardial infarction
based on euglycemic hyperinsulinemic clamp. Am J Physiol Endocrinol
Metab 2014, 306(4):E399–E403.
33. American Diabetes Association: Diagnosis and classification of diabetes
mellitus. Diabetes Care 2014, 37(Suppl.1):S81–S90.
34. Balkau B, Charles M, for European Group for the Study of Insulin Resistance
(EGIR): Comment on the provisional report from the WHO consultation.
Diabet Med 1999, 16:442–443.
35. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek
JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Using
standardized serum creatinine values in the modification of diet in renal
disease study equation for estimating glomerular filtration rate. Ann
Intern Med 2006, 145:247–254.
36. Rentrop KP, Cohen M, Blanke H, Phillips RA: Changes in collateral channel
filling immediately after controlled coronary artery occlusion by an angioplasty
balloon in human subjects. J Am Coll Cardiol 1985, 5(3):587–592.
37. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P,
Passamani ER, Williams DO, Zaret B: The effect of intravenous
thrombolytic therapy on left ventricular function: a report on tissue-type
plasminogen activator and streptokinase from the Thrombolysis in
Myocardial Infarction (TIMI Phase I) trial. Circulation 1987, 75(4):817–829.
38. Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, White
HD, van ‘t Hof AW, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW:
ST-segment recovery and outcome after primary percutaneous coronary
intervention for ST-elevation myocardial infarction: insights from the
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI)
trial. Circulation 2008, 118:1335–1346.
39. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, Sakuma H,
Hartiala J: Coronary flow reserve: measurement with transthoracic
Doppler echocardiography is reproducible and comparable with
positron emission tomography. Clin Physiol 2001, 21(1):114–122.
40. Djordjevic-Dikic A, Beleslin B, Stepanovic J, Giga V, Tesic M, Dobric M, Stojkovic S,
Nedeljkovic M, Vukcevic V, Dikic N, Petrasinovic Z, Nedeljkovic I, Tomasevic M,
Vujisic-Tesic B, Ostojic M: Prediction of myocardial functional recovery by
noninvasive evaluation of basal and hyperemic coronary flow in patients with
previous myocardial infarction. J Am Soc Echocardiogr 2011, 24(5):573–581.
41. Rigo F, Varga Z, Di Pede F, Grassi G, Turiano G, Zuin G, Coli U, Raviele A,
Picano E: Early assessment of coronary flow reserve by transthoracic
Doppler echocardiography predicts late remodeling in reperfused
anterior myocardial infarction. J Am Soc Echocardiogr 2004, 17(7):750–755.
42. Li L, Messina JL: Acute insulin resistance following injury. Trends Endocrinol
Metab 2009, 20(9):429–435.
43. Pretty CG, Le Compte AJ, Chase JG, Shaw GM, Preiser JC, Penning S, Desaive T:
Variability of insulin sensitivity during the first 4 days of critical illness:
implications for tight glycemic control. Ann Intensive Care 2012, 2(1):17.
44. Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O: Insulin
resistance and inflammation markers in myocardial infarction. J Inflamm
Res 2013, 6:83–90.
45. Xiao C, Giacca A, Carpentier A, Lewis GF: Differential effects of monounsaturated,
polyunsaturated and saturated fat ingestion on glucose-stimulated insulin
secretion, sensitivity and clearance in overweight and obese, non-diabetic
humans. Diabetologia 2006, 49:1371–1379.
46. Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM: Implications for
carbohydrate-based bolus dose calculation and intensive diabetes man-
agement. Diabetes Care 2013, 36(4):810–816.
47. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive
drugs: a network meta-analysis. Lancet 2007, 369:201–207.
48. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai
SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott
DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM,
Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto
Trifunovic et al. Cardiovascular Diabetology 2014, 13:73 Page 12 of 12
http://www.cardiab.com/content/13/1/73AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, et al: Statins and risk
of incident diabetes: a collaborative meta-analysis of randomised statin
trials. Lancet 2010, 375(9716):735–742.
49. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA,
Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA,
Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident
diabetes with intensive-dose compared with moderate-dose statin
therapy: a meta-analysis. JAMA 2011, 305(24):2556–2564.
50. Yong AS, Fearon WF: Coronary microvascular dysfunction after
ST-segment-elevation myocardial infarction: local or global
phenomenon? Circ Cardiovasc Interv 2013, 6(3):201–203.
51. Eroglu S, Sade LE, Bozbas H, Haberal A, Ozbicer S, Demir O, Muderrisoglu H:
Association of serum adiponectin levels and coronary flow reserve in
women with normal coronary angiography. Eur J Cardiovasc Prev Rehabil
2009, 16(3):290–296.
52. Kondo I, Mizushige K, Hirao K, Nozaki S, Tsuji T, Masugata H, Kohno M,
Matsuo H: Ultrasonographic assessment of coronary flow reserve and
abdominal fat in obesity. Ultrasound Med Biol 2001, 27(9):1199–1205.
53. Snoer M, Monk-Hansen T, Olsen RH, Pedersen LR, Simonsen L, Rasmusen H,
Dela F, Prescott E: Insulin resistance and exercise tolerance in heart failure
patients: linkage to coronary flow reserve and peripheral vascular
function. Cardiovasc Diabetol 2012, 11:97.
54. Timmer J, Ottervanger J, de Boer M, Dambrink JE, Hoorntje JCA, Gosselink
ATM, Suryapranata H, Zijlstra F, Van’t Hof AWJ, for the Zwolle Myocardial
Infarction Study Group: Hyperglycemia is an important predictor of
impaired coronary flow before reperfusion therapy in ST-segment
elevation myocardial infarction. J Am Coll Cardiol 2005, 45(7):999–1002.
55. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T,
Tanaka K, Masuyama T, Hori M, Fujii K: Association between hyperglycemia
and the no-reflow phenomenon in patients with acute myocardial
infarction. J Am Coll Cardiol 2003, 41(1):1–7.
56. Monnier L, Mas E, Ginet C, Michel F, Willon L, Cristol JP, Colette C:
Activation of oxidative stress by acute glucose fluctuations compared
with sustained chronic hyperglycemia in patients with type 2 diabetes.
JAMA 2006, 295:1681–1687.
57. Chang J, Zhang G, Zhang L, Hou YP, Liu XL, Zhang L: High admission
glucose levels increase Fas apoptosis and mortality in patients with
acute ST-elevation myocardial infarction: a prospective cohort study.
Cardiovasc Diabetol 2013, 12(1):171.
58. Sundell J, Nuutila P, Laine H, Luotolahti M, Kalliokoski K, Raitakari O, Knuuti J:
Dose-dependent vasodilating effects of insulin on adenosine-stimulated
myocardial blood flow. Diabetes 2002, 51(4):1125–1130.
59. Laine H, Nuutila P, Luotolahti M, Meyer C, Elomaa T, Koskinen P, Rönnemaa
T, Knuuti J: Insulin-induced increment of coronary flow reserve is not
abolished by dexamethasone in healthy young men. J Clin Endocrinol
Metab 2000, 85(5):1868–1873.
60. Rocchini AP, Wilson RF, Marker P, Cervenka T: Metabolic and
hemodynamic effects of a graded intracoronary insulin infusion in
normal and fat anesthetized dogs: a preliminary study. Hypertension 1996,
27(3):354–359.
61. Sundell J, Laine H, Luotolahti M, Kalliokoski K, Raitakari O, Nuutila P, Knuuti J:
Obesity affects myocardial vasoreactivity and coronary flow response to
insulin. Obes Res 2002, 10(7):617–624.
62. L’Huillier I, Zeller M, Mock L, Beer JC, Laurent Y, Sicard P, Vincent-Martin M,
Lorgis L, Makki H, Wolf JE, Freysz M, Cottin Y: Relation of hyperglycemia to
ST-segment resolution after reperfusion for acute myocardial infarction
(from Observatoire des Infarctus de Côte-d’Or Survey [RICO]). Am J
Cardiol 2006, 98(2):167–171.
63. Chi HJ, Zhang DP, Xu Y, Yang ZS, Wang LF, Cui L, Yang XC: Relation of
hyperglycemia to ST-segment resolution after primary percutaneous
coronary intervention for acute myocardial infarction. Chin Med J (Engl)
2007, 120(21):1874–1877.
doi:10.1186/1475-2840-13-73
Cite this article as: Trifunovic et al.: Acute insulin resistance in
ST-segment elevation myocardial infarction in non-diabetic patients is
associated with incomplete myocardial reperfusion and impaired coronary
microcirculatory function. Cardiovascular Diabetology 2014 13:73.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
